[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MD20150092A2 - Derivate ale amidelor pentru tratamentul infecţiei cu HIV - Google Patents

Derivate ale amidelor pentru tratamentul infecţiei cu HIV

Info

Publication number
MD20150092A2
MD20150092A2 MDA20150092A MD20150092A MD20150092A2 MD 20150092 A2 MD20150092 A2 MD 20150092A2 MD A20150092 A MDA20150092 A MD A20150092A MD 20150092 A MD20150092 A MD 20150092A MD 20150092 A2 MD20150092 A2 MD 20150092A2
Authority
MD
Moldova
Prior art keywords
formula
treatment
hiv infection
amide derivatives
disclosed
Prior art date
Application number
MDA20150092A
Other languages
English (en)
Russian (ru)
Inventor
Гедиминас Брызгис
Эда Каналес
Чиэнь-хун Чоу
Майкл Граупе
Юньфэн Эрик Ху
Джон О. Линк
Ц Лю
Яфань Лу
Роланд Д. САИТО
Скотт Д. Шрёдер
Джон Р. Сомоза
Уинстон С. Це
Дженнифер Р. Чжан
Скотт Е. Лазервит
Рэндалл ХАЛКОМБ
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50382584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20150092(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20150092A2 publication Critical patent/MD20150092A2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sunt dezvăluiţi compuşi cu formula I:Isau sărurile acestora. De asemenea, sunt dezvăluite compoziţiile farmaceutice ce conţin un compus cu formula I, procedeele de obţinere a compuşilor cu formula I, intermediarii utili pentru obţinerea compuşilor cu formula I şi metodele terapeutice de tratament al infecţiei virale Retroviridae, inclusiv al infecţiei cu HIV.
MDA20150092A 2013-03-01 2014-02-28 Derivate ale amidelor pentru tratamentul infecţiei cu HIV MD20150092A2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771655P 2013-03-01 2013-03-01
US201361857636P 2013-07-23 2013-07-23
PCT/US2014/019663 WO2014134566A2 (en) 2013-03-01 2014-02-28 Therapeutic compounds

Publications (1)

Publication Number Publication Date
MD20150092A2 true MD20150092A2 (ro) 2016-02-29

Family

ID=50382584

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150092A MD20150092A2 (ro) 2013-03-01 2014-02-28 Derivate ale amidelor pentru tratamentul infecţiei cu HIV

Country Status (38)

Country Link
US (4) US20140303164A1 (ro)
EP (3) EP3954679A3 (ro)
JP (5) JP6519486B2 (ro)
KR (1) KR102229989B1 (ro)
CN (2) CN108516974A (ro)
AP (1) AP2015008717A0 (ro)
AU (3) AU2014223973B2 (ro)
BR (1) BR112015021027B1 (ro)
CA (2) CA2901502C (ro)
CL (1) CL2015002445A1 (ro)
CR (2) CR20190504A (ro)
CU (1) CU24340B1 (ro)
CY (1) CY1121047T1 (ro)
DK (1) DK2961742T3 (ro)
EA (1) EA035127B1 (ro)
ES (2) ES2887578T3 (ro)
HK (3) HK1222169A1 (ro)
HR (1) HRP20181679T1 (ro)
HU (1) HUE039521T2 (ro)
IL (1) IL240519B (ro)
LT (1) LT2961742T (ro)
MD (1) MD20150092A2 (ro)
MX (1) MX2015011478A (ro)
MY (1) MY195364A (ro)
NZ (3) NZ631754A (ro)
PE (2) PE20191461A1 (ro)
PH (1) PH12015501881A1 (ro)
PL (2) PL3409667T3 (ro)
PT (2) PT3409667T (ro)
RS (1) RS57718B1 (ro)
SG (2) SG11201506929VA (ro)
SI (2) SI3409667T1 (ro)
SM (1) SMT201800522T1 (ro)
TW (2) TWI706945B (ro)
UA (1) UA120346C2 (ro)
UY (1) UY35362A (ro)
WO (1) WO2014134566A2 (ro)
ZA (1) ZA201506098B (ro)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
EP2943487B1 (en) 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI706945B (zh) * 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
MX2015010775A (es) * 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
US10526323B2 (en) 2015-01-30 2020-01-07 Vanderbilt University Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
PT3286166T (pt) * 2015-04-23 2020-08-18 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
WO2016172425A1 (en) 2015-04-23 2016-10-27 Viiv Healthcare (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20170040479A1 (en) 2015-08-07 2017-02-09 Solaero Technologies Corp. Reliable interconnection of solar cells
US20170081324A1 (en) * 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease
US10493070B2 (en) 2016-06-30 2019-12-03 Viiv Healthcare Uk (No. 5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
WO2018002849A1 (en) 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
EP3478661A1 (en) 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Aza-substituted inhibitors of human immunodeficiency virus replication
PE20211427A1 (es) * 2016-08-19 2021-08-03 Gilead Sciences Inc Compuestos terapeuticos utiles para el tratamiento profilatico o terapeutico de una infeccion por el virus del vih
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
UY37710A (es) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
BR112020010581A2 (pt) 2017-12-07 2020-11-10 Emory University composição farmacêutica, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e de tratamento ou prevenção de coronavírus humano, sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus chikungunya e infecção por infecção de ross river, vírus orthomyxoviridae ou vírus paramyxoviridae ou vírus rsv, ou infecção pelo vírus influenza a e vírus influenza b ou vírus filoviridae ou vírus ebola.
US10836746B2 (en) * 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
AR114631A1 (es) * 2018-02-16 2020-09-30 Gilead Sciences Inc Métodos e intermedios para preparar compuestos de piridina
JP7307747B2 (ja) * 2018-04-11 2023-07-12 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての４－オキソ－３，４－ジヒドロキナゾリン化合物
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
US11958834B2 (en) 2018-08-09 2024-04-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3849982A1 (en) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3853228A1 (en) 2018-09-20 2021-07-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020084491A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3870575B1 (en) 2018-10-25 2023-03-29 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7526174B2 (ja) 2018-10-29 2024-07-31 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド キナゾリニル－インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用
EP3876942A1 (en) 2018-11-05 2021-09-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3877387A1 (en) 2018-11-05 2021-09-15 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
US20220211704A1 (en) 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
AU2020295793B2 (en) 2019-06-19 2023-07-06 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
WO2021064571A1 (en) 2019-10-01 2021-04-08 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
JP2022551256A (ja) 2019-10-01 2022-12-08 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
WO2021108544A1 (en) 2019-11-26 2021-06-03 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
JPWO2021107066A1 (ro) 2019-11-28 2021-06-03
WO2021104413A1 (zh) * 2019-11-29 2021-06-03 江苏恒瑞医药股份有限公司 稠合吡啶环衍生物、其制备方法及其在医药上的应用
CN115135647A (zh) * 2020-01-30 2022-09-30 先正达农作物保护股份公司 杀有害生物活性的稠合二环杂芳香族氨基化合物
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
IL296182A (en) * 2020-03-06 2022-11-01 Viiv Healthcare Uk No 5 Ltd Inhibitors of human immunodeficiency virus replication
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
AU2021256166B2 (en) 2020-04-15 2024-05-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7520162B2 (ja) * 2020-06-25 2024-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの治療のためのカプシド阻害剤
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2021377614A1 (en) 2020-11-11 2023-06-22 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022247942A1 (zh) * 2021-05-28 2022-12-01 江苏恒瑞医药股份有限公司 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
WO2024220624A1 (en) 2023-04-19 2024-10-24 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
WO2024257009A1 (en) * 2023-06-15 2024-12-19 VIIV Healthcare UK (No.5) Limited Methods and intermediates for preparing compounds
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080108539A (ko) * 2006-04-12 2008-12-15 머크 앤드 캄파니 인코포레이티드 피리딜 아미드 ｔ-형 칼슘 채널 길항제
MX2010004530A (es) * 2007-10-24 2010-05-14 Merck Sharp & Dohme Antagonistas de los canales de calcio tipo t de heterociclo fenil amida.
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
CA2707418C (en) 2007-11-16 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
US20120045761A1 (en) 2009-02-25 2012-02-23 Bigtec Private Limited Probes and primers for detection of chikungunya
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110035387A1 (en) * 2009-08-10 2011-02-10 Telcordia Technologies, Inc. System and method for the controlled introduction of noise to information filtering
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
BR112013000043A2 (pt) 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido naft-2-ilacético para tratar aids
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CN103702561B (zh) 2011-03-23 2017-02-22 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
CA2840095A1 (en) * 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) * 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US20140155381A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
AU2013249041B2 (en) 2012-04-20 2016-11-03 Gilead Sciences, Inc. Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an HIV infection
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943487B1 (en) 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
US10035760B2 (en) 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2016172425A1 (en) 2015-04-23 2016-10-27 Viiv Healthcare (No.5) Limited Inhibitors of human immunodeficiency virus replication
PT3286166T (pt) 2015-04-23 2020-08-18 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
JP6620763B2 (ja) * 2017-01-16 2019-12-18 マツダ株式会社 電動車両

Also Published As

Publication number Publication date
EP3409667B1 (en) 2021-07-21
US20210009555A1 (en) 2021-01-14
ZA201506098B (en) 2022-05-25
TWI694071B (zh) 2020-05-21
CR20190504A (es) 2020-03-11
BR112015021027A2 (pt) 2017-07-18
PT3409667T (pt) 2021-09-16
CY1121047T1 (el) 2019-12-11
JP2022009742A (ja) 2022-01-14
IL240519A0 (en) 2015-10-29
BR112015021027A8 (pt) 2020-01-14
JP2018141018A (ja) 2018-09-13
NZ742681A (en) 2019-05-31
EA201591457A8 (ru) 2018-05-31
NZ631754A (en) 2017-02-24
HK1222169A1 (zh) 2017-06-23
CU20150096A7 (es) 2016-07-29
AP2015008717A0 (en) 2015-09-30
PE20191461A1 (es) 2019-10-16
PH12015501881B1 (en) 2016-01-11
EP3409667A1 (en) 2018-12-05
SG11201506929VA (en) 2015-10-29
IL240519B (en) 2020-11-30
CL2015002445A1 (es) 2016-02-19
AU2016262671B2 (en) 2018-11-08
PL3409667T3 (pl) 2021-12-13
UY35362A (es) 2014-08-29
JP6519486B2 (ja) 2019-05-29
US20160108030A1 (en) 2016-04-21
PE20151749A1 (es) 2015-12-12
ES2887578T3 (es) 2021-12-23
RS57718B1 (sr) 2018-12-31
CN105705500B (zh) 2018-05-29
CA2901502A1 (en) 2014-09-04
EP3954679A2 (en) 2022-02-16
TW201446755A (zh) 2014-12-16
AU2018247348A1 (en) 2018-11-08
CA3007006A1 (en) 2014-09-04
WO2014134566A2 (en) 2014-09-04
HK1226078B (zh) 2017-09-22
CN108516974A (zh) 2018-09-11
KR102229989B1 (ko) 2021-03-18
SI2961742T1 (sl) 2018-11-30
SMT201800522T1 (it) 2018-11-09
CU24340B1 (es) 2018-05-08
EA035127B1 (ru) 2020-04-30
CN105705500A (zh) 2016-06-22
EP3954679A3 (en) 2022-04-20
PT2961742T (pt) 2018-10-26
ES2688571T3 (es) 2018-11-05
EA201591457A1 (ru) 2016-03-31
PL2961742T3 (pl) 2018-12-31
PH12015501881A1 (en) 2016-01-11
CR20150454A (es) 2015-11-20
TW201938551A (zh) 2019-10-01
AU2014223973A1 (en) 2015-09-10
CA2901502C (en) 2018-07-17
UA120346C2 (uk) 2019-11-25
KR20150121720A (ko) 2015-10-29
JP2016510038A (ja) 2016-04-04
EP2961742A2 (en) 2016-01-06
MX2015011478A (es) 2016-02-03
LT2961742T (lt) 2018-09-25
MY195364A (en) 2023-01-16
HK1260892A1 (zh) 2019-12-27
SG10201710764YA (en) 2018-02-27
AU2014223973B2 (en) 2016-12-22
WO2014134566A3 (en) 2014-12-24
BR112015021027B1 (pt) 2020-02-18
AU2016262671A1 (en) 2016-12-08
HUE039521T2 (hu) 2019-01-28
TWI706945B (zh) 2020-10-11
HRP20181679T1 (hr) 2018-12-14
US20180273508A1 (en) 2018-09-27
NZ728537A (en) 2018-08-31
SI3409667T1 (sl) 2021-11-30
US9951043B2 (en) 2018-04-24
JP6893899B2 (ja) 2021-06-23
JP2019214599A (ja) 2019-12-19
US20140303164A1 (en) 2014-10-09
EP2961742B1 (en) 2018-08-01
JP2023101723A (ja) 2023-07-21
DK2961742T3 (en) 2018-09-24

Similar Documents

Publication Publication Date Title
MD20150092A2 (ro) Derivate ale amidelor pentru tratamentul infecţiei cu HIV
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
NZ729150A (en) Antiretroviral agents
NZ631738A (en) (hetero) arylacetamide derivatives as antiretroviral agents
PH12019500335A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
NZ631762A (en) 5-membered heteroaryls and their use as antiviral agents
PH12017501258A1 (en) Pyrazine compounds for the treatment of infectious diseases
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
MD4602B1 (ro) Inhibitori ai virusului hepatic C
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
GEP20156263B (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for production and usage thereof
PH12019550113A1 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
MY182353A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
MX2018015990A (es) Compuestos terapeuticos.
CY1118920T1 (el) Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)